OS Therapies Inc. OSTX 深 沪
等待开盘 10-11 09:30:00 美东时间
1.99
-0.050
-2.45%
华盛通- 最 高2.10
- 今 开2.10
- 成交量 145.49万股
- 最 低 1.9541
- 昨 收 2.04
- 总市值 6297.36万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 4.60%
- 52周最低 1.12
- 委 比 31.97%
- 总股本 3164.50万
- 历史最高 7.00
- 量 比 4.49
- 振 幅 7.15%
- 历史最低 1.12
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Announces Positive Regulatory Update Following October 6 Meeting With EMA Rapporteur, Dutch Medicines Evaluation Board
Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma settings, supported
10-09 19:43
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
09-12 23:22
OS Therapies To Release Updated 2-Yr Survival Data For OST-HER2 In Phase 2b Osteosarcoma Trial On October 10, 2025
Concurrent with this announcement, the Company announced that updated 2-year overall survival data from all 40 patients in the Company's Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully
09-12 19:44
OS Therapies Raises $3.7M for OST-HER2 Launch
The latest announcement is out from OS Therapies Incorporated ( ($OSTX) ). On S...
09-03 04:50
OS Therapies To Provide FDA Meeting Update On OST-HER2 Regulatory Path For Osteosarcoma On September 2, 2025
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed
08-28 04:13
OS Therapies Reports Progress in Osteosarcoma Treatment
OS Therapies Incorporated ( ($OSTX) ) has released its Q2 earnings. Here is a b...
08-26 12:01
OS Therapies reports Q2 results
OS Therapies press release (NYSE:OSTX): Q2 Reported final EFS data (35% vs. 20%, p = 0.0197) showing a statistically significant benefit from the Company's 40 patient Phase 2b clinical trial for OST-...
08-20 03:21
OS Therapies Q2 EPS $(0.19) Misses $(0.12) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 65.22 percent. This is a 26.92 percent increase over losses of $(0.26) per share from the
08-19 18:07
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
